HTL Biotechnology inaugurates a new production line dedicated to sterile Hyaluronic Acid
As part of National Biomanufacturing Day 2025, HTL Biotechnology inaugurates a new production line dedicated to Hyaluronic Acid.
“This project can be replicated because it’s a way of thinking about flows. By taking a step back, thinking about flows in a different way and involving people on the ground, management and all teams, we get different perspectives on flows. This allows us to adapt and find more comprehensive solutions.”
HTL Biotechnology has reviewed its flow management and dedicated each of its two distillation columns to a single product. On-site alcohol consumption has been reduced, as have the volume of hazardous waste and the associated impacts (direct and indirect costs, particularly management and logistics). The operation of the distillation unit has been automated and optimised.
Results:
– A reduction in gas consumption of more than 25% 1,000 tonnes of CO2 equivalent saved in 2022 across scopes 1, 2 and 3, representing 8% of the site’s emissions
– A 68% reduction in hazardous waste thanks to alcohol recycling
– Project management involving operators from the design phase onwards, which was subsequently replicated.
This October, HTL Biotechnology turned pink to support breast cancer prevention.
The European Society of Cataract and Refractive Surgeons (ESCRS) is a unique opportunity each year to connect with our clients and partners while gaining insights into the key trends shaping the future of ophthalmology.
We’re pleased to share our second CSR report, highlighting the actions and commitments we carried out throughout 2024.